Hypogonadism and cardiovascular diseases in men


The article analyses correlation between low levels of sex hormones in men (male hypogonadism) and cardiovascular diseases. It was believed for a long time that androgens have adverse effect on cardiovascular system. It is shown that, on the contrary, hypogonadism indirectly raises the risk of cardiovascular diseases via various components of metabolic syndrome. Moreover, correction of male hypogonadism with testosterone preparations may have a positive effect on risk factors of vascular complications including fat reduction , normalization of blood pressure, correction of dyslipidemia. Pharmacologically, testosterone undecanoate for intramuscular injections (nebido) is a good form. This drug can provide a stable physiological testosterone level for about 12 weeks after injection.

About the authors

Safail Ogly Gamidov

Email: docand@rambler.ru

Oleg Khalitovich Tazhetdinov

Vyacheslav Vasil'evich Iremashvili

S I Gamidov

N.I. Pirogov Russian State Medical University, Moscow; I.M. Sechenov First Moscow State Medical University

N.I. Pirogov Russian State Medical University, Moscow; I.M. Sechenov First Moscow State Medical University

O Kh Tazhetdinov

N.I. Pirogov Russian State Medical University, Moscow

N.I. Pirogov Russian State Medical University, Moscow

V V Iremashvili

N.I. Pirogov Russian State Medical University, Moscow

N.I. Pirogov Russian State Medical University, Moscow


  1. Мазо Е. Б., Гамидов С. И., Иремашвили В. В., Гасанов P. В. Патогенез эректильной дисфункции при метаболическом синдроме. Вестн. РАМН, 2008; 2: 21-26.
  2. Wu F. C., von Eckardstein A. Androgens and coronary artery disease. Endocr. Rev 2003; 24: 183-217.
  3. Jones R. D., Nettleship J. E., Kapoor D. et al. Testosterone and atherosclerosis in aging men: purported association and clinical implications. Am. J. Cardiovasc. Drugs 2005; 5: 141-154.
  4. Hak A. E., Witteman J. C., de Jong F. H. et al. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J. Clin. Endocrinol. 2002; 87: 3632-3639.
  5. Svartberg J. Epidemiology: testosterone and the metabolic syndrome. Int. J. Impot. Res. 2007; 19: 124-128.
  6. Hajjar R. R., Kaiser F. E., Morley J. E. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J. Clin. Endocrinol. 1997; 82: 3793-3796.
  7. Shabsigh R., Katz M., Yan G., Makhsida N. Cardiovascular issues in hypogonadism and testosterone therapy. Am. J. Cardiol. 2005; 96: 67M-72M.
  8. English K. M., Steeds R. P., Jones T. H. et al. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. Circulation 2000; 102: 1906-1911.
  9. Malkin C. J., Pugh P. J., West J. N. et al. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur. Heart J. 2006; 27: 57-64.
  10. Khaw K. T., Dowsett M., Folkerd E. et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 2007; 116: 2694-2701.
  11. Maggio M., Lauretani F., Ceda G. P. et al. Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the Chianti Area (InCHIANTI) study. Arch. Intern. Med. 2007; 167: 2249-2254.
  12. Araujo A. B., Kupelian V., Page S. T. et al. Sex steroids and all-cause and cause-specific mortality in men. Arch. Intern. Med. 2007; 167: 1252-1260.
  13. Laaksonen D. E., Niskanen L., Punnonen К. et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabet. Care 2004; 27: 1036-1041.
  14. Stellato R. K., Feldman H. A., Hamdy O. et al. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabet. Care 2000; 23: 490- 494.
  15. Muller M., Grobbee D. E., den Tonkelaar I. et al. Endogenous sex hormones and metabolic syndrome in aging men. J. Clin. Endocrinol. 2005; 90: 2618-2623.
  16. Kapoor D., Malkin C. J., Channer K. S., Jones T. H. Androgens, insulin resistance and vascular disease in men. Clin. Endocrinol. (Oxf.) 2005; 63: 239-250.
  17. Holmang A., Bjorntorp P. The effects of testosterone on insulin sensitivity in male rats. Acta Physiol. Scand. 1992; 146: 505- 510.
  18. Yesilova Z., Oktenli С., Sanisoglu S. Y. et al. Evaluation of insulin sensitivity in patients with Klinefelter's syndrome: a hyperinsulinemic euglycemic clamp study. Endocrine 2005; 27: 11-15.
  19. Hakimian P., Blute M., Jr., Kashanian J. et al. Metabolic and cardiovascular effects of androgen deprivation therapy. Br. J. Urol. Int. 2008; 102: 1509-1514.
  20. Tomar R., Dhindsa S., Chaudhuri A. et al. Contrasting testosterone concentrations in type 1 and type 2 diabetes. Diabet. Care 2006; 29: 1120-1122.
  21. Kapoor D., Goodwin E., Charmer K. S., Jones T. H. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur. J. Endocrinol. 2006; 154: 899-906.
  22. Pitteloud N., Hardin M., Dwyer A. A. et al. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J. Clin. Endocrinol. 2005; 90: 2636- 2641.
  23. Pasquali R., Casimirri F., De Iasio R. et al. Insulin regulates testosterone and sex hormone-binding globulin concentrations in adult normal weight and obese men. J. Clin. Endocrinol. 1995; 80: 654-658.
  24. Plymate S. R., Matej L. A., Jones R. E., Friedl K. E. Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J. Clin Endocrinol. 1988; 67: 460-464.
  25. Zumoff B., Strain G. W., Miller L. K. et al. Plasma free and non-sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J. Clin. Endocrinol. 1990; 71: 929-931.
  26. Haffner S. M., Valdez R. A., Stern M. P., Katz M. S. Obesity, body fat distribution and sex hormones in men. Int. J. Obes. Relat. Metab. Disord. 1993; 17: 643-649.
  27. Guerre-Millo М. Adipose tissue hormones. J. Endocrinol. Invest. 2002; 25: 855-861.
  28. Blouin K., Boivin A., Tchernof A. Androgens and body fat distribution. J. Steroid Biochem. Mol. Biol. 2008; 108: 272-280.
  29. Isidori A. M., Caprio M., Strollo F. et al. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J. Clin. Endocrinol. 1999; 84: 3673-3680.
  30. Wake D. J., Strand M., Rask E. et al. Intra-adipose sex steroid metabolism and body fat distribution in idiopathic human obesity. Clin. Endocrinol. (Oxf.) 2007; 66: 440-446.
  31. De Pergola G. The adipose tissue metabolism: role of testosterone and dehydroepiandrosterone. Int. J. Obes. Relat. Metab. Disord. 2000; 24(Suppl. 2): S59-S63.
  32. Singh R., Artaza J. N., Taylor W. E. et al. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology 2003; 144: 5081-5088.
  33. Cohen P. G. The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt~a major factor in the genesis of morbid obesity. Med. Hypothes. 1999; 52: 49-51.
  34. Haffner S. M., Mykkanen L., Valdez R. A., Katz M. S. Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. J. Clin. Endocrinol. 1993; 77: 1610-1615.
  35. Barud W., Palusinski R., Beltowski J., Wojcicka G. Inverse relationship between total testosterone and anti-oxidized low density lipoprotein antibody levels in ageing males. Atherosclerosis 2002; 164: 283-283.
  36. Van Pottelbergh I., Braeckman L., De Bacquer D. et al. Differential contribution of testosterone and estradiol in the determination of cholesterol and lipoprotein profile in healthy middle-aged men. Atherosclerosis 2003; 166: 95-102.
  37. Svartberg J., von Muhlen D., Schirmer H. et al. Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromso Study. Eur J Endocrinol, 2004; 150: 65-71.
  38. Lu Y. L., Kuang L., Zhu H. et al. Changes in aortic endothelium ultrastructure in male rats following castration, replacement with testosterone and administration of 5alpha-reductase inhibitor. Asian J. Androl. 2007; 9: 843-847.
  39. Foresta C., Zuccarello D., De Toni L. et al. Androgens stimulate endothelial progenitor cells through an androgen receptor-mediated pathway. Clin Endocrinol. (Oxf.) 2008; 68: 284- 289.
  40. Liu D., Iruthayanathan M., Homan L. L. et al. Dehydroepiandrosterone stimulates endothelial proliferation and angiogenesis through extracellular signal-regulated kinase 1/2-mediated mechanisms. Endocrinology 2008; 149: 889-898.
  41. Liu D., Si H., Reynolds K. A. et al. Dehydroepiandrosterone protects vascular endothelial cells against apoptosis through a Galphai protein-dependent activation of phosphatidylinositol 3-kinase/Akt and regulation of antiapoptotic Bcl-2 expression. Endocrinology 2007; 148: 3068-3076.
  42. Kumanov P., Tomova A., Kirilov G. Testosterone replacement therapy in male hypogonadism is not associated with increase of endothelin-1 levels. Int. J. Androl. 2007; 30: 41-47.
  43. Norata G. D., Tibolla G., Seccomandi P. M. et al. Dihydrotestosterone decreases tumor necrosis factor-alpha and lipopolysaccharide-induced inflammatory response in human endothelial cells. J. Clin. Endocrinol. 2006; 91: 546-554.
  44. Bowles D. K., Maddali K. K., Dhulipala V. C., Korzick D. H. PKCdelta mediates anti-proliferative, pro-apoptic effects of testosterone on coronary smooth muscle. Am. J. Physiol. Cell Physiol. 2007; 293: С805-C813.
  45. Williams M. R., Ling S., Dawood T. et al. Dehydroepiandrosterone inhibits human vascular smooth muscle cell proliferation independent of ARs and ERs. J. Clin. Endocrinol. 2002; 87: 176-181.
  46. Basaria S., Dobs A. S. Hypogonadism and androgen replacement therapy in elderly men. Am. J. Med. 2001; 110: 563- 572.
  47. Harle L., Basaria S., Dobs A. S. Nebido: a long-acting injectable testosterone for the treatment of male hypogonadism. Expert. Opin. Pharmacother. 2005; 6: 1751-1759.
  48. Behre H. M., von Eckardstein S., Kliesch S., Nieschlag E. Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7-10 years. Clin. Endocrinol. (Oxf.) 1999; 50: 629-635.
  49. Jordan W. P., Jr. Allergy and topical irritation associated with transdermal testosterone administration: a comparison of scrotal and nonscrotal transdermal systems. Am. J. Contact Dermat. 1997; 8: 108-113.
  50. Nieschlag E. Testosterone treatment comes of age: new options for hypogonadal men. Clin. Endocrinol. (Oxf.) 2006; 65: 275- 281.
  51. Morgentaler A., Lipshultz L. I., Bennett R. et al. Testosterone therapy in men with untreated prostate cancer. J. Urol. (Baltimore) 2011; 185: 1256-1261.
  52. Rebuffe-Scrive M., Marin P., Bjorntorp P. Effect of testosterone on abdominal adipose tissue in men. Int. J. Obes. 1991; 15: 791-795.
  53. Tenover J. S. Effects of testosterone supplementation in the aging male. J. Clin. Endocrinol. 1992; 75: 1092-1098.
  54. Marin P. Testosterone and regional fat distribution. Obes. Res. 1995; 3(Suppl. 4). 609S-612S.
  55. Snyder P. J., Peachey H., Hannoush P. et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J. Clin. Endocrinol. 1999; 84: 2647-2653.
  56. Wang C., Swerdloff R. S., Iranmanesh A. et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J. Clin. Endocrinol. 2000; 85: 2839-2853.
  57. Kenny A. M., Prestwood K. M., Gruman C. A. et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J. Gerontol. A. Biol. Sci. Med. Sci. 2001; 56: M266-M272.
  58. Simon D., Charles M. A., Lahlou N. et al. Androgen therapy improves insulin sensitivity and decreases leptin level in healthy adult men with low plasma total testosterone: a 3-month randomized placebo-controlled trial. Diabet. Care 2001; 24; 2149-2151.
  59. Wittert G. A., Chapman I. M., Haren M. T. et al. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J. Gerontol. A. Biol. Sci. Med. Sci 2003; 58: 618-625.
  60. Boyanov M. A., Boneva Z., Christov V. G. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003; 6: 1-7.
  61. Naharci M. I., Pinar M., Bolu E., Olgun A. Effect of testosterone on insulin sensitivity in men with idiopathic hypogonadotropic hypogonadism. Endocr. Pract 2007; 13: 629-635.
  62. Saad F., Gooren L. J., Haider A., Yassin A. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. J. Androl. 2008; 29: 102-105.
  63. Agledahl I., Hansen J. B., Svartberg J. Impact of testosterone treatment on postprandial triglyceride metabolism in elderly men with subnormal testosterone levels. Scand. J. Clin. Lab. Invest. 2008; 68: 641-648.
  64. Allan C. A., Strauss B. J., Burger H. G. et al. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J. Clin. Endocrinol. 2008; 93: 139-146.
  65. Zitzmann M., Nieschlag E. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J. Clin. Endocrinol. 2007; 92: 3844-3853.
  66. Filippi S., Vignozzi L., Morelli A. et al. Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome. J. Sex. Med. 2009; 6: 3274-3288.
  67. Li J. Y., Zhu J. C., Dou J. T. et al. Effects of androgen supplementation therapy on partial androgen deficiency in the aging male: a preliminary study. Aging Male 2002; 5: 47-51.
  68. Tan К. С., Shiu S. W., Pang R. W., Kung A. W. Effects of testosterone replacement on HDL subfractions and apolipoprotein A-I containing lipoproteins. Clin. Endocrinol. (Oxf.) 1998; 48: 187-194.
  69. Ozata M., Yildirimkaya M., Bulur M. et al. Effects of gonadotropin and testosterone treatments on Lipoprotein(a), high density lipoprotein particles, and other lipoprotein levels in male hypogonadism. J. Clin. Endocrinol. 1996; 81: 3372- 3378.
  70. Guler N., Batyraliev T., Dulger H. et al. The effects of short term (3 weeks) testosterone treatment on serum inflammatory markers in men undergoing coronary artery stenting. Int. J. Cardiol. 2006; 109: 339-343.
  71. Foresta C., Caretta N., Lana A. et al. Reduced number of circulating endothelial progenitor cells in hypogonadal men. J. Clin. Endocrinol. 2006; 91: 4599-4602.
  72. Yue P., Chatterjее К., Beale С. et al. Testosterone relaxes rabbit coronary arteries and aorta. Circulation 1995; 91: 1154-1160.
  73. Webb C. M., McNeill J. G., Hayward C. S. et al. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 1999; 100: 1690-1696.
  74. Hamm L. Testosterone propionate in the treatment of angina pectoris. J. Clin. Endocrinol. 1942; 2: 325-328.
  75. Jaffe M. D. Effect of testosterone cypionate on postexercise ST segment depression. Br. Heart J. 1977; 39: 1217-1222.
  76. Wu S. Z., Weng X. Z. Therapeutic effects of an androgenic preparation on myocardial ischemia and cardiac function in 62 elderly male coronary heart disease patients. Chin. Med. J. (Engl.) 1993; 106: 415-418.
  77. Rosano G. M., Leonardo F., Pagnotta P. et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 1999; 99: 1666-1670.
  78. Webb C. M., Adamson D. L., de Zeigler D., Collins P. Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am. J. Cardiol. 1999; 83: 437-439, A9.
  79. Malkin C. J., Pugh P. J., Morris P. D. et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart 2004; 90: 871-876.



Abstract - 106


Article Metrics

Metrics Loading ...


  • There are currently no refbacks.

Copyright (c) 2011 Gamidov S.O., Tazhetdinov O.K., Iremashvili V.V., Gamidov S.I., Tazhetdinov O.K., Iremashvili V.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:


© 2018 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies